Sponsored by Vaccinex.
For an in-depth explanation of the trial, visit the Huntington Study Group’s web page here.
The SIGNAL trial is designed to assess the safety, tolerability, and effectiveness of VX15, a novel monoclonal antibody, in people with late prodromal (not yet diagnosed) or early manifest (early in the progression of the disease) HD. It is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study being conducted at approximately 30 sites across the United States and Canada. The trial seeks to enroll a total of 240 individuals, 21 or older.
This study is currently recruiting participants.
A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington’s Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503
The SIGNAL trial is a Randomized Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503 in Subjects at Risk for or with Early Signs of Huntington’s Disease
Canadian Locations and Contact Information:
Location: University of Alberta
Coordinator: Paul McCann
Location: University of British Columbia
Coordinator: Tuan Lee
Exclusion Criteria (eligibility that would exclude you from this study)
- Have participated in an investigational drug or device study within 30 days of the Baseline Visit
- Have had previous neurosurgery for HD or other movement disorders.
- Have a history of malignancy of any type within 2 years prior to Screening.
- Inability to undergo brain MRI.
- Visit here for more exclusion and inclusion criteria.
For more detailed information on this study and others and for the most recent updates, please go to clinicaltrials.gov ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.